KeyBanc lowered the firm’s price target on Absci to $6 from $8 and keeps an Overweight rating on the shares. The firm’s credit card data continues to show healthy utilization levels across hospital systems post the Change Healthcare outage, with hospital customer levels up high single digits in May and June year over year, but the ongoing robust employment data for healthcare systems keeps the firm wary of potential spending for hospital-exposed names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
- Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Intuit initiated, Charter downgraded: Wall Street’s top analyst calls
- Absci initiated with an Overweight at Morgan Stanley
- Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference